SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on May 13, 2021. The filing serves as a current report to announce the issuance of a press release detailing financial results for the quarter ended March 31, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, WA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing these details, but the text of the press release is not included in the provided input.
Material Changes
No specific material changes versus the prior comparable period are quantified in this document. The filing solely indicates that results for the quarter ended March 31, 2021, have been reported.
Guidance, Outlook, and Risks
- Disclosure Channels: The company utilizes its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Facebook) to disseminate material information regarding product candidates and other matters.
- Regulation FD: The filing includes a Regulation FD disclosure statement, noting that information released through the aforementioned channels may be deemed material.
- Legal Status: The information furnished under Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 13, 2021), as they are absent from this 8-K text.
- Confirm the company name is Athira Pharma, Inc. (Ticker: ATHA), noting the discrepancy with the "Leonabio, Inc." label in the request metadata.
- Review the company's official investor relations website and social media channels for any additional material updates referenced in the Regulation FD disclosure.
- Check subsequent filings for the full audited financial statements corresponding to the quarter ended March 31, 2021.